Overactive bladder

STIMVIA Unveils Innovative Solution to Transform CNS Disorder Treatments at TechCrunch Disrupt 2023

Retrieved on: 
Wednesday, September 20, 2023
Tremor, TechCrunch, Incontinence, Woman, Brain, Electrode, Parkinson's disease, Patient, SAN, Algorithm, Overactive bladder, Conditional sentence, Skin, Pharmaceutical industry, Medical imaging

STIMVIA has made remarkable progress in the treatment of this condition.

Key Points: 
  • STIMVIA has made remarkable progress in the treatment of this condition.
  • STIMVIA's commitment to innovation is confirmed by its participation in TechCrunch Disrupt 2023 as part of Start-up Battlefield 200 – the most prestigious competition for start-ups.
  • We can activate centres that are underactive and conversely, dampen the activity of regions showing excessive activity," explains Lukas Doskocil, CEO of STIMVIA.
  • This fall, STIMVIA will also initiate a pilot study to assess URIS® technology's suitability for Parkinson's disease and essential tremor patients.

STIMVIA Unveils Innovative Solution to Transform CNS Disorder Treatments at TechCrunch Disrupt 2023

Retrieved on: 
Monday, September 11, 2023
Tremor, TechCrunch, Incontinence, Woman, Brain, Electrode, Parkinson's disease, Patient, SAN, Algorithm, Overactive bladder, Conditional sentence, Skin, Medical imaging, Pharmaceutical industry

STIMVIA has made remarkable progress in the treatment of this condition.

Key Points: 
  • STIMVIA has made remarkable progress in the treatment of this condition.
  • STIMVIA's commitment to innovation is confirmed by its participation in TechCrunch Disrupt 2023 as part of Start-up Battlefield 200 – the most prestigious competition for start-ups.
  • We can activate centres that are underactive and conversely, dampen the activity of regions showing excessive activity," explains Lukas Doskocil, CEO of STIMVIA.
  • This fall, STIMVIA will also initiate a pilot study to assess URIS® technology's suitability for Parkinson's disease and essential tremor patients.

Sinaptica Appoints Ken Mariash as Chief Executive Officer

Retrieved on: 
Wednesday, May 24, 2023
Mental Health, Medical Devices, FDA, Seniors, Clinical Trials, Biotechnology, Health, Consumer, General Health, University of Oxford, Therapy, CSL Behring, Marketing, Baxter, Pathology, Business, Business economics, CRA International, EBT, Multimedia, Strategic planning, Economics, Amyloid, HIV disease progression rates, Patient, Oxford University Press, Neuromodulation, Investment, Associate, Brown University, System, Overactive bladder, R, AD, Medtech, Memory, BD, Pharmaceutical industry, Takeda, Boston Scientific, Biochemistry, Brain

Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer.

Key Points: 
  • Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer.
  • As Chief Executive Officer, Mariash joins the company to accelerate clinical product development of the company’s SinaptiStim™ System, a closed-loop neuromodulation therapy that utilizes a novel approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory.
  • “As Sinaptica prepares for a pivotal clinical trial of our closed-loop neuromodulation therapy, Ken is the ideal choice to lead the company through this important stage,” said Rich Macary, President of Sinaptica Therapeutics.
  • Prior to EBT, Mariash was Director, Strategy and New Markets for the nearly $1B Neuromodulation division of Boston Scientific.

ObjectiveHealth Announces Clinical Research Partnership With Urology of St. Louis

Retrieved on: 
Tuesday, May 23, 2023
Research, Clinical Trials, Health Technology, Other Health, Health, General Health, Other Science, Science, Oncology, Partnership, Gastroenterology, Physician, Biomarker, Urology, Urinary tract infection, Dermatology, Metro East, Patient, Standard of care, Medicine, Overactive bladder, Biology, Kidney stone disease, Prostate cancer, Hospital, Medical imaging, Nursing

ObjectiveHealth , a Nashville-based integrated research and technology platform company, today announced a clinical research partnership with Urology of St. Louis .

Key Points: 
  • ObjectiveHealth , a Nashville-based integrated research and technology platform company, today announced a clinical research partnership with Urology of St. Louis .
  • The companies’ joint clinical research center, Specialty Clinical Research of St. Louis , will offer access to innovative diagnostic tools, treatments and therapies aimed at improving health outcomes in urologic disease states.
  • Urology of St. Louis has 27 practicing urology associates at 21 locations throughout St. Louis and the Metro East.
  • “We’re proud to offer access to more treatment options for urology patients through our new partnership with Urology of St. Louis,” said Colleen Hoke, co-founder and chief executive officer of ObjectiveHealth.

Pierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladder

Retrieved on: 
Monday, May 22, 2023
Contract management, Pierre Fabre, Quality of life, Single person, Gesellschaft mit beschränkter Haftung, EMA, OAB, BP, Urology, Patient, Overactive bladder, Heart rate, Urinary incontinence, Safety, Pharmaceutical industry, EU, Vibegron

CASTRES, France, May 22, 2023 /PRNewswire/ -- Following the exclusive licensing agreement with Urovant Sciences GmbH, Pierre Fabre announced today the start of the EU marketing authorization application procedure (centralized procedure) for Vibegron, a novel, potent, and selective human β3 adrenergic receptor (β 3-AR) agonist inducing muscle relaxation to increase bladder capacity and relieve symptoms of overactive bladder (OAB).

Key Points: 
  • CASTRES, France, May 22, 2023 /PRNewswire/ -- Following the exclusive licensing agreement with Urovant Sciences GmbH, Pierre Fabre announced today the start of the EU marketing authorization application procedure (centralized procedure) for Vibegron, a novel, potent, and selective human β3 adrenergic receptor (β 3-AR) agonist inducing muscle relaxation to increase bladder capacity and relieve symptoms of overactive bladder (OAB).
  • Results from this study confirm that Vibegron 75 mg had no statistically significant or clinically meaningful effects on BP or HR in patients with symptoms of OAB.
  • "The submission of the Vibegron application to the EMA is another important milestone for Pierre Fabre, which reinforces its long-standing commitment to the field of urology.
  • For more information about Pierre Fabre, please visit www.pierre-fabre.com .

Women’s Health Leader Elidah Launches Game-changing ELITONE URGE Device To Treat Overactive Bladder

Retrieved on: 
Tuesday, May 2, 2023
Incontinence, Quality of life, Woman, Trial of the century, Hyperkinesia, OAB, OTC, Urology, Overactive bladder, FDA, Dietary supplement

This latest device, a natural successor to ELITONE, is specified to treat urgency bladder leaks that afflict 33 million women in the United States alone.

Key Points: 
  • This latest device, a natural successor to ELITONE, is specified to treat urgency bladder leaks that afflict 33 million women in the United States alone.
  • ELITONE URGE is an external, non-implanted muscle stimulator that outputs signals to calm the muscles and nerves that cause urgency or OAB leaks.
  • ELITONE URGE received FDA-clearance recently to treat urgency leaks after achieving clinically significant leak reduction for 76% of study participants after just 6 weeks of treatment.
  • “Before ELITONE URGE, there were no efficacious at-home treatments for OAB leaks,” explains Gloria Kolb, CEO of Elidah.

Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting

Retrieved on: 
Monday, May 1, 2023
AUA, American Urological Association, Overactive bladder, Blue Wind, OAB, Annual general meeting, Urology, FDA, ITT, PARK, Safety, Urinary incontinence, Medical imaging

The results were featured in the late-breaking session ( LBA01-05 ) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago on Sunday, April 30th.

Key Points: 
  • The results were featured in the late-breaking session ( LBA01-05 ) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago on Sunday, April 30th.
  • The presentation at this preeminent Urology conference demonstrates both the unique design of Blue Wind's innovative technology, as well as the strength of the clinical evidence.
  • "We are grateful to the investigators and study participants who made OASIS possible," said Dan Lemaitre, Chief Executive Officer of BlueWind Medical.
  • We continue to work with the FDA and look forward to introducing this innovative solution to physicians and patients."

Urologists Explore the Validity of Urologic Information on Social Media

Retrieved on: 
Friday, April 28, 2023
Maimonides Medical Center, Interview, Culture, Politics, Communication, Social media, Public, DO, OAB, Patient, Physician, Overactive bladder, Social, Health

Quality of Overactive Bladder Videos on Social Media: What is the Public Learning from TikTok? "

Key Points: 
  • Quality of Overactive Bladder Videos on Social Media: What is the Public Learning from TikTok? "
  • "For better or worse, social media has become an integral part of the average American's life.
  • It has impacted our culture, our politics, and now we are starting to learn, potentially our health," said Dr. Dubin.
  • "A large portion of Americans are turning towards YouTube, TikTok, Instagram and other social media platforms for health problems before ever consulting a healthcare provider.

BlueWind Medical to Present Positive Results from its Pivotal Trial in Patients with Overactive Bladder at the 2023 AUA Annual Meeting

Retrieved on: 
Monday, April 24, 2023
Nexus, Urine, AUA, American Urological Association, Overactive bladder, Maastricht, International Continence Society, OAB, MD, Patient, Annual general meeting, Urology, PARK, Safety, Pharmaceutical industry

In addition, the company was selected to present at the inaugural AUA Innovation Nexus on April 27th and will exhibit its novel BlueWind System at the AUA conference.

Key Points: 
  • In addition, the company was selected to present at the inaugural AUA Innovation Nexus on April 27th and will exhibit its novel BlueWind System at the AUA conference.
  • BlueWind Medical will be presenting the 12 month data at the AUA Late-Breaking Abstract Session LBA01 on April 30th from 7:00 to 9:00 am CT in room S505.
  • OAB can manifest in UUI, the involuntary leakage of urine associated with a sudden compelling desire to void.
  • "We are pleased with the positive results from OASIS and look forward to presenting these important data at AUA."

Avation Medical Announces US FDA 510(k) Clearance for The Vivally® System, a wearable bladder control therapy and mobile app to treat patients with urinary urgency and urge urinary incontinence

Retrieved on: 
Tuesday, April 11, 2023
Sir Vival, US Food Sovereignty Alliance, Tibial nerve, EMG, Food and Drug Administration, Woman, Multimedia, Sale, Electromyography, OAB, Patient, Urination, Overactive bladder, FDA, Food, Urinary incontinence, Dentistry, Medical imaging, Pharmaceutical industry, COLUMBUS

COLUMBUS, Ohio, April 11, 2023 /PRNewswire/ -- Avation Medical, Inc., the innovator in patient-friendly, closed-loop neuromodulation options to treat life-altering medical conditions, today announced that its Vivally System received US Food and Drug Administration (FDA) 510(k) clearance. Vivally is a non-invasive, bladder control therapy device and mobile application to treat patients with the conditions of urinary urgency and urge urinary incontinence (UUI) caused by overactive bladder (OAB) syndrome, without the need for surgery, drugs, or needle-electrodes. The Vivally System is the only closed-loop, non-invasive neuromodulation system for bladder control cleared for sale in the United States. Closed-loop control objectively confirms activation of the tibial nerve and continuously adjusts therapy parameters to ensure optimal output throughout the session.

Key Points: 
  • Revolutionary smart bladder control system provides new option, allowing patients to conduct therapy at-home without surgery, implants, or drugs.
  • Vivally is a non-invasive, bladder control therapy device and mobile application to treat patients with the conditions of urinary urgency and urge urinary incontinence (UUI) caused by overactive bladder (OAB) syndrome, without the need for surgery, drugs, or needle-electrodes.
  • The Vivally System is the only closed-loop, non-invasive neuromodulation system for bladder control cleared for sale in the United States.
  • Closed-loop control objectively confirms activation of the tibial nerve and continuously adjusts therapy parameters to ensure optimal output throughout the session.